Imbalance between procoagulant factors and natural coagulation inhibitors contributes to hypercoagulability in the critically ill COVID-19 patient: clinical implications.
Aged
Area Under Curve
Betacoronavirus
/ isolation & purification
Blood Coagulation Factor Inhibitors
/ metabolism
Blood Coagulation Factors
/ metabolism
Body Mass Index
COVID-19
Coronavirus Infections
/ complications
Critical Illness
Factor V
/ analysis
Factor VIII
/ analysis
Female
Fibrin Fibrinogen Degradation Products
/ analysis
Fibrinogen
/ analysis
Humans
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ complications
Protein C
/ analysis
Protein S
/ analysis
ROC Curve
SARS-CoV-2
Venous Thromboembolism
/ complications
Journal
European review for medical and pharmacological sciences
ISSN: 2284-0729
Titre abrégé: Eur Rev Med Pharmacol Sci
Pays: Italy
ID NLM: 9717360
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
entrez:
23
9
2020
pubmed:
24
9
2020
medline:
2
10
2020
Statut:
ppublish
Résumé
Coronavirus Disease-2019 (COVID-19) predisposes patients to thrombosis which underlying mechanisms are still incompletely understood. We sought to investigate the balance between procoagulant factors and natural coagulation inhibitors in the critically ill COVID-19 patient and to evaluate the usefulness of hemostasis parameters to identify patients at risk of venous thromboembolic event (VTE). We conducted an observational study recording VTEs defined as deep vein thrombosis or pulmonary embolism using lower limb ultrasound (92% of the patients), computed tomography pulmonary angiography (6%) and both tests (2%). We developed a comprehensive analysis of hemostasis. Ninety-two consecutive mechanically ventilated COVID-19 patients (age, 62 years [53-69] (median [25th-75th percentiles]); M/F sex ratio, 2.5; body-mass index, 28 kg/m2 [25-32]; past hypertension (52%) and diabetes mellitus (30%)) admitted to the Intensive Care Unit (ICU) from 03/11/2020 to 5/05/2020, were included. When tested, patients were receiving prophylactic (74%) or therapeutic (26%) anticoagulation. Forty patients (43%) were diagnosed with VTE. Patients displayed inflammatory and prothrombotic profile including markedly elevated plasma fibrinogen (7.7 g/L [6.1-8.6]), D-dimer (3,360 ng/mL [1668-7575]), factor V (166 IU/dL [136-195]) and factor VIII activities (294 IU/dL [223-362]). We evidenced significant discrepant protein C anticoagulant and chromogenic activities, combined with slightly decreased protein S activity. Plasma D-dimer >3,300 ng/mL predicted VTE presence with 78% (95%-confidence interval (95% CI), 62-89) sensitivity, 69% (95% CI, 55-81) specificity, 66% (95% CI, 51-79) positive predictive value and 80% (95% CI, 65-90) negative predictive value [area under the ROC curve, 0.779 (95%CI, 0.681-0.859), p=0.0001]. Mechanically ventilated COVID-19 patients present with an imbalance between markedly increased factor V/VIII activity and overwhelmed protein C/S pathway. Plasma D-dimer may be a useful biomarker at the bedside for suspicion of VTE.
Identifiants
pubmed: 32965009
doi: 10.26355/eurrev_202009_22866
pii:
doi:
Substances chimiques
Blood Coagulation Factor Inhibitors
0
Blood Coagulation Factors
0
Fibrin Fibrinogen Degradation Products
0
Protein C
0
Protein S
0
fibrin fragment D
0
Factor V
9001-24-5
Factor VIII
9001-27-8
Fibrinogen
9001-32-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM